Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Medical Devices
- Sub-Industry: N/A
- Symbol: NASDAQ:NVTR
- CUSIP: N/A
- Web: www.nuvectramed.com
- Market Cap: $143.66 million
- Outstanding Shares: 10,342,000
- 50 Day Moving Avg: $9.99
- 200 Day Moving Avg: $7.49
- 52 Week Range: $4.63 - $15.00
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.36
- P/E Growth: 0.00
- Annual Revenue: $15.51 million
- Price / Sales: 9.21
- Book Value: $7.35 per share
- Price / Book: 1.88
- EBIDTA: ($40,650,000.00)
- Net Margins: -286.26%
- Return on Equity: -47.33%
- Return on Assets: -36.79%
- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 4.51%
- Quick Ratio: 4.19%
- Average Volume: 60,984 shs.
- Beta: 1.2
- Short Ratio: 1.38
Frequently Asked Questions for Nuvectra Corporation (NASDAQ:NVTR)
What is Nuvectra Corporation's stock symbol?
Nuvectra Corporation trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra Corporation's earnings last quarter?
Nuvectra Corporation (NASDAQ:NVTR) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.25) by $0.02. The firm earned $5 million during the quarter, compared to analysts' expectations of $4.61 million. Nuvectra Corporation had a negative net margin of 286.26% and a negative return on equity of 47.33%. The business's quarterly revenue was up 47.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.70) earnings per share. View Nuvectra Corporation's Earnings History.
Where is Nuvectra Corporation's stock going? Where will Nuvectra Corporation's stock price be in 2017?
2 brokers have issued 12 month price targets for Nuvectra Corporation's shares. Their forecasts range from $10.00 to $12.00. On average, they anticipate Nuvectra Corporation's stock price to reach $11.00 in the next year. View Analyst Ratings for Nuvectra Corporation.
Who are some of Nuvectra Corporation's key competitors?
Some companies that are related to Nuvectra Corporation include Syndax Pharmaceuticals (SNDX), Organovo Holdings (ONVO), Curis (CRIS), Kamada (KMDA), Voyager Therapeutics (VYGR), Quotient Limited (QTNT), Veracyte (VCYT), Cerus Corporation (CERS), Corium International (CORI), Idera Pharmaceuticals (IDRA), Nabriva Therapeutics AG (NBRV), Fortress Biotech (FBIO), Zynerba Pharmaceuticals (ZYNE), Chimerix (CMRX), Tabula Rasa Healthcare (TRHC), Advaxis (ADXS), Oxford Biomedica (OXBDF) and Corvus Pharmaceuticals (CRVS).
Who owns Nuvectra Corporation stock?
Nuvectra Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (8.20%), Dimensional Fund Advisors LP (6.59%), Vanguard Group Inc. (2.83%), Laurel Wealth Advisors Inc. (1.94%), Hodges Capital Management Inc. (1.86%) and Essex Investment Management Co. LLC (1.38%). Company insiders that own Nuvectra Corporation stock include David D Johnson, Joseph A Miller, Scott F Drees and Thomas Kelley Hickman. View Institutional Ownership Trends for Nuvectra Corporation.
Who sold Nuvectra Corporation stock? Who is selling Nuvectra Corporation stock?
Nuvectra Corporation's stock was sold by a variety of institutional investors in the last quarter, including Tudor Investment Corp ET AL, Goldman Sachs Group Inc., Sessa Capital IM L.P., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Laurel Wealth Advisors Inc. and California Public Employees Retirement System. View Insider Buying and Selling for Nuvectra Corporation.
Who bought Nuvectra Corporation stock? Who is buying Nuvectra Corporation stock?
Nuvectra Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Gilder Gagnon Howe & Co. LLC, Essex Investment Management Co. LLC, Hodges Capital Management Inc., FNY Partners Fund LP, Vanguard Group Inc., Wells Fargo & Company MN and Stifel Financial Corp. Company insiders that have bought Nuvectra Corporation stock in the last two years include David D Johnson, Joseph A Miller and Scott F Drees. View Insider Buying and Selling for Nuvectra Corporation.
How do I buy Nuvectra Corporation stock?
Shares of Nuvectra Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuvectra Corporation's stock price today?
MarketBeat Community Rating for Nuvectra Corporation (NASDAQ NVTR)MarketBeat's community ratings are surveys of what our community members think about Nuvectra Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Nuvectra Corporation stock can currently be purchased for approximately $13.81.
Consensus Ratings for Nuvectra Corporation (NASDAQ:NVTR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$11.00 (20.35% downside)|
Analysts' Ratings History for Nuvectra Corporation (NASDAQ:NVTR)
(Data available from 6/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|5/15/2017||B. Riley||Reiterated Rating||Buy||$12.00||High|
|8/13/2016||Piper Jaffray Companies||Reiterated Rating||Neutral||$12.00 -> $10.00||N/A|
|6/3/2016||Sterne Agee CRT||Initiated Coverage||Buy||$14.00||N/A|
Earnings History for Nuvectra Corporation (NASDAQ:NVTR)Earnings History by Quarter for Nuvectra Corporation (NASDAQ NVTR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2017||Q1 2017||($1.25)||($1.27)||$4.61 million||$5.00 million||View||Listen|
|3/7/2017||Q4 2016||($0.89)||($1.27)||$3.97 million||$4.20 million||View||Listen|
|11/9/2016||Q3 2016||($0.88)||($0.92)||$2.81 million||$3.80 million||View||Listen|
|8/10/2016||Q216||($1.13)||($0.85)||$2.40 million||$2.50 million||View||Listen|
Earnings Estimates for Nuvectra Corporation (NASDAQ:NVTR)
2017 EPS Consensus Estimate: ($4.54)
2018 EPS Consensus Estimate: ($3.17)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Nuvectra Corporation (NASDAQ:NVTR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nuvectra Corporation (NASDAQ:NVTR)
Institutional Ownership Percentage: 58.42%Insider Trades by Quarter for Nuvectra Corporation (NASDAQ:NVTR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/30/2017||Scott F Drees||CEO||Buy||7,395||$10.41||$76,981.95|| |
|5/25/2017||Scott F Drees||CEO||Buy||2,605||$9.92||$25,841.60|| |
|3/16/2017||Joseph A Miller||Director||Buy||25,000||$6.11||$152,750.00|| |
|3/14/2017||Scott F Drees||CEO||Buy||25,000||$6.21||$155,250.00|| |
|1/4/2017||Thomas Kelley Hickman||EVP||Sell||133||$5.36||$712.88|| |
|5/19/2016||David D Johnson||Director||Buy||30,000||$14.02||$420,600.00|| |
Headline Trends for Nuvectra Corporation (NASDAQ:NVTR)
Latest Headlines for Nuvectra Corporation (NASDAQ:NVTR)
|Nuvectra Files Regulatory Submission with FDA for Algovita® MRI-Conditional Approval|
finance.yahoo.com - June 21 at 8:14 PM
|Nuvectra Corporation (NVTR) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - June 21 at 4:42 PM
|TheStreet Upgrades Nuvectra Corporation (NVTR) to C-|
www.americanbankingnews.com - June 21 at 2:28 PM
| Nuvectra Corporation (NVTR) Receives Consensus Rating of "Strong Buy" from Brokerages|
www.americanbankingnews.com - June 21 at 7:48 AM
|Nuvectra Corporation (NVTR) Rating Increased to Hold at ValuEngine|
www.americanbankingnews.com - June 17 at 12:32 AM
|ETFs with exposure to Nuvectra Corp. : June 16, 2017|
finance.yahoo.com - June 16 at 7:55 PM
|ETFs with exposure to Nuvectra Corp. : June 5, 2017|
finance.yahoo.com - June 5 at 7:34 PM
|Nuvectra Corp. :NVTR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017|
finance.yahoo.com - June 2 at 8:47 PM
|Scott F. Drees Purchases 7,395 Shares of Nuvectra Corp (NVTR) Stock|
www.americanbankingnews.com - June 1 at 8:32 PM
|Nuvectra Corp (NVTR) Raised to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - May 30 at 8:56 PM
|Brokerages Anticipate Nuvectra Corp (NVTR) to Announce ($1.24) EPS|
www.americanbankingnews.com - May 29 at 4:34 PM
|Nuvectra Corp (NVTR) CEO Purchases $25,841.60 in Stock|
www.americanbankingnews.com - May 26 at 4:46 PM
|Nuvectra Corp (NVTR) Sees Large Growth in Short Interest|
www.americanbankingnews.com - May 21 at 11:14 AM
|Nuvectra Corp (NVTR) Rating Reiterated by B. Riley|
www.americanbankingnews.com - May 14 at 10:14 PM
|Zacks Investment Research Downgrades Nuvectra Corp (NVTR) to Sell|
www.americanbankingnews.com - May 13 at 9:40 AM
|Nuvectra Corp Expected to Post Q2 2017 Earnings of ($1.24) Per Share (NVTR)|
www.americanbankingnews.com - May 12 at 8:50 AM
|Nuvectra Corp (NVTR) Releases Earnings Results, Misses Estimates By $0.02 EPS|
www.americanbankingnews.com - May 9 at 11:02 PM
|Nuvectra Corporation misses by $0.02, beats on revenue|
seekingalpha.com - May 9 at 6:35 PM
|Nuvectra™ Reports First Quarter 2017 Financial Results|
www.nasdaq.com - May 9 at 6:35 PM
|Nuvectra Corporation (NVTR) Misses Q1 EPS by 2c, Beat on Revenues|
www.streetinsider.com - May 9 at 6:35 PM
|Nuvectra reports 1Q loss|
marketbeat.com - May 9 at 5:44 PM
|Investor Network: Nuvectra Corp. to Host Earnings Call|
finance.yahoo.com - May 9 at 11:27 AM
|Nuvectra to Present at the 18th Annual B. Riley Co. Investor Conference|
finance.yahoo.com - May 3 at 8:07 PM
|Nuvectra to Report First Quarter 2017 Financial Results on May 9, 2017|
finance.yahoo.com - April 27 at 10:08 AM
|ETFs with exposure to Nuvectra Corp. : April 26, 2017|
finance.yahoo.com - April 26 at 6:20 PM
|ETFs with exposure to Nuvectra Corp. : April 5, 2017|
finance.yahoo.com - April 7 at 11:38 AM
|Nuvectra Announces Cowen & Company Hosted Physician Panel on Spinal Cord Stimulation on March 29, 2017|
finance.yahoo.com - March 27 at 10:00 AM
|Zacks: Analysts Set $12.00 Price Target for Nuvectra Corp (NVTR)|
www.americanbankingnews.com - March 22 at 10:31 AM
|Nuvectra Corp (NVTR) Director Acquires $152,750.00 in Stock|
www.americanbankingnews.com - March 20 at 7:55 PM
|NUVECTRA CORP Financials|
finance.yahoo.com - March 15 at 7:07 PM
|NUVECTRA CORP Files SEC form 10-K, Annual Report|
biz.yahoo.com - March 9 at 6:46 PM
|Nuvectra Corporation (NVTR) Presents At Cowen and Company 37th Annual Health Care Conference|
seekingalpha.com - March 8 at 7:42 PM
|Q4 2016 Nuvectra Corp Earnings Release - Before Market Open|
us.rd.yahoo.com - March 7 at 11:47 PM
|Nuvectra™ Reports Fourth Quarter and Full Year 2016 Financial Results|
www.nasdaq.com - March 7 at 10:02 AM
|Nuvectra Corporation misses by $0.38, beats on revenue|
seekingalpha.com - March 7 at 10:02 AM
|NUVECTRA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits|
biz.yahoo.com - March 7 at 10:02 AM
|Nuvectra to Present at the 29th Annual ROTH Conference|
finance.yahoo.com - March 6 at 8:04 AM
|Nuvectra to Present at the Cowen and Company 37th Annual Health Care Conference|
finance.yahoo.com - March 1 at 10:30 AM
|Nuvectra to Report Fourth Quarter 2016 Financial Results on March 7, 2017|
finance.yahoo.com - February 21 at 5:56 PM
|Nuvectra Extends Timeline of Existing Credit Facility|
us.rd.yahoo.com - February 14 at 10:12 PM
|Nuvectra to Present at the Leerink Partners 6th Annual Global Healthcare Conference|
finance.yahoo.com - February 6 at 9:26 AM
|Nuvectra Files Regulatory Submissions for FDA and CE Mark Approvals of the Virtis™ Sacral Nerve Stimulation (SNS) System|
us.rd.yahoo.com - February 1 at 8:04 PM
|10:01 am Nuvectra files regulatory submissions with the FDA and CE Mark authorities for Virtis|
us.rd.yahoo.com - February 1 at 8:04 PM
|NUVECTRA CORP Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - January 17 at 7:18 PM
|Nuvectra Receives Frost & Sullivan’s New Product Innovation Award for Its Algovita® SCS System|
finance.yahoo.com - January 17 at 11:25 AM
|Nuvectra Corporation Signs Direct Supply Agreement|
finance.yahoo.com - December 12 at 9:57 AM
|8:01 am Nuvectra completes a direct supply agreement with Minnetronix; will begin purchasing the external peripheral devices for its Algovita spinal cord stimulation system directly from Minnetronix in the first half of 2017 as it transitio|
finance.yahoo.com - December 12 at 9:57 AM
|Nuvectra to Present at the 28th Annual Piper Jaffray Healthcare Conference|
finance.yahoo.com - November 21 at 11:52 AM
|Nuvectra Corporation misses by $0.04, beats on revenue|
seekingalpha.com - November 10 at 9:37 AM
|Q3 2016 Nuvectra Corp Earnings Release - After Market Close|
biz.yahoo.com - November 9 at 9:03 AM
Nuvectra Corporation (NVTR) Chart for Thursday, June, 22, 2017